Humana (NYSE:HUM) Releases FY 2025 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 16.250-16.250 for the period, compared to the consensus earnings per share estimate of 16.410. The company issued revenue guidance of -.

Analysts Set New Price Targets

Several equities research analysts have commented on HUM shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Piper Sandler upped their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Barclays boosted their price target on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. Morgan Stanley dropped their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. Eighteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $285.68.

Humana Trading Down 0.0 %

NYSE HUM opened at $264.55 on Wednesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a market cap of $31.93 billion, a P/E ratio of 26.59, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The stock has a 50 day simple moving average of $269.37 and a two-hundred day simple moving average of $272.67. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, analysts forecast that Humana will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s payout ratio is 35.58%.

Institutional Trading of Humana

A hedge fund recently bought a new stake in Humana stock. Revolve Wealth Partners LLC acquired a new position in Humana Inc. (NYSE:HUM) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 798 shares of the insurance provider’s stock, valued at approximately $202,000. 92.38% of the stock is currently owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.